Bioassays Currently Available for Evaluating the Biological Potency of Pharmaceuticals in Treated Wastewater

Abstract

Water deprivation with regard to quantity and quality is one of the most important environmental problems of the century. The increasing demand of water resources puts pressure on the utilization of alternative sources such as treated wastewater. In the context of "reduce, reuse, and recycle," the inclusion of treated wastewater in the water cycle seems a promising practice for water management. The lack of general acceptance of stakeholders and public, however, still hinders the widespread application of wastewater reuse. A reason for this is, among others, the presence of contaminants of emerging concern in treated wastewater. This has led to an increased concern about direct and indirect effects to the environment and possible implications to human health. The development and application of bioassays able to identify and quantify the biological potency of treated wastewater is an ongoing research effort, especially when taking into consideration that a plethora of contaminants exist and interact in this complex matrix. This chapter summarizes available literature regarding the sensitivity of currently applied bioassays for assessing biological effects of treated wastewater and their correlation with chemical analysis. The focus is on pharmaceuticals since they represent one of the major groups of contaminants of emerging concern with many unanswered questions currently in place.

Diclofenac biodegradation by newly isolated Klebsiella sp. KSC: Microbial intermediates and ecotoxicological assessment

“…It has been included in the list of priority hazardous compounds [9]. Diclofenac has been found to be toxic at the low μg/L levels in chronic exposures of different organisms like fish and mussels, as reviewed in Vasquez et al [10]. Interestingly, a permanent shift of the microbial community composition of a wastewater treatment bioreactor was observed after an exposure to diclofenac at 50 pg/L [11].…”

Environmental Risks of Pharmaceutical Mixtures in Aquatic Ecosystems: Reflections on a Decade of Research

“…However, this quickly leads to immense resource requirements, especially for heterogeneous mixtures and investigations of apical effects on whole organisms. Numerous bioassays now exist for APIs found in effluents (Vasquez et al, 2016), and EDA is being applied to surface waters, sediments, and even biological tissues (Simon et al, 2015). However, if the TIE or EDA is focused on a particular group of chemicals with similar modes of action, fewer simpler and more specific high‐throughput assays (e.g., receptor‐activation assays) can be used.…”